Acurex Biosciences moves 15-lipoxygenase program closer to Parkinson’s disease clinical testing
Parkinson’s drugs still treat symptoms. Acurex’s ASAP grant puts 15-lipoxygenase and ferroptosis into sharper disease-modifying focus.
Coya Therapeutics advances COYA 302 as FDA fast track status raises clinical expectations
Coya Therapeutics’ COYA 302 fast track status raises the stakes for Treg-based ALS therapy. Find out what comes next.
Why Oragenics, Inc. is betting on CardioDialysis technology to expand its TBI platform
Why is Oragenics, Inc. expanding into CardioDialysis for TBI treatment? Explore the strategy, risks, and future implications today.
How Bioxodes is positioning BIOX-101 for accelerated approval in intracerebral hemorrhage
Can BIOX-101 become the first disease-modifying therapy for intracerebral hemorrhage? Explore Bioxodes’ accelerated approval strategy.
Why BioVie Inc.’s Phase 2 bezisterim data could shift the Parkinson’s disease treatment paradigm
Explore how BioVie Inc.’s bezisterim could reshape Parkinson’s treatment strategies ahead of Phase 2 data. Find out what it means for the industry.
Can Evommune turn EVO756 into a cross-indication inflammatory franchise with migraine next?
Evommune is taking EVO756 into migraine prophylaxis. Read why MRGPRX2 inhibition could matter, and what risks still cloud the story.
Ventyx to give Lilly an oral inflammation pipeline—what’s the real upside?
Eli Lilly and Company has announced plans to acquire Ventyx Biosciences Inc. in an all-cash transaction valued at approximately $1.2 billion, securing a portfolio of clinical-stage oral small molecule therapeutics focused on chronic inflammatory-mediated diseases. The deal includes NLRP3 inhibitors such as VTX2735 and VTX3232, alongside two Phase 2 programs for inflammatory bowel disease. The […]
Can CK0804 overcome JAK inhibitor resistance in myelofibrosis and reshape the Treg cell therapy landscape?
Cellenkos, Inc., a clinical-stage biotechnology company developing allogeneic regulatory T cell (Treg) therapies, has unveiled new data from its investigational product CK0804, presented at the 67th American Society of Hematology (ASH) Annual Meeting. The findings highlight the potential of a dose-intensive regimen of CK0804 to reduce spleen volume, improve symptoms, and lower transfusion dependence in […]
What makes LNK01006 a potentially best-in-class TYK2 inhibitor with central immune impact?
Lynk Pharmaceuticals and Formation Bio have entered an exclusive licensing and development agreement for LNK01006, a next-generation, central nervous system (CNS)-penetrant TYK2 inhibitor. The deal gives Formation Bio global rights to the asset outside Greater China, with plans to initiate a Phase 1 clinical trial in the United States during the first half of 2026. […]